<p>The multiplex assay screened one compound (100 μM) against three enzymes. The activity of <i>Pf</i>A-M1 and—M17 were measured by change in fluorescence units over time. No inhibitor controls (n = 8) for <i>Pf</i>MAP activity were included in each plate screened (shown in orange). A representative of the ‘drug-like’ compounds (MMV403679) is indicated by asterisk (*). A ‘probe-like’ compound (MMV666023) by solid dots (•). The inhibitor control (Bestatin) is shown as a solid black line.</p
Left panel. Structure of the compounds. Right panel. Commercially available derivatives of FMP-40131...
A difficulty associated with high throughput screening for enzyme inhibitors is to establish reactio...
<p><b>A.</b> Scheme of the plate design in 96-well format for compounds screening. <b>B. Left, </b><...
<p>Enzyme activity in the presence of 100 μM compound (MMV# shown) was compared to activity of the e...
<p>Curves represent the sigmoidal fittings of the data, obtained in triplicates, on PmV inhibition b...
<p>(<b>A</b>) Inhibition potencies of the candidate compounds. The magnitudes of inhibition by compo...
<p>Scatter plot of primary screening data where the percentage of infected cells was normalized with...
<p>(A, B) Non-fluorescent inhibitors, compounds 3 and 14; the decrease in fluorescence is inhibited ...
<p>(A) Screening data of the 85 compounds investigated in the FluoPol assay. A 15% cut-off was set t...
Secreted active proteases, from families of enzymes such as matrix metalloproteinases (MMPs) and ADA...
(a-b) Preliminary screen outcome of 400 drug-like molecules in Pathogen Box as a measure of percenta...
<p>The plate format is shown. Column 1 contains maximum inhibition control (rifampicin) in Rows A–D ...
<div><p>A difficulty associated with high throughput screening for enzyme inhibitors is to establish...
<p>The different steps, the most relevant assay conditions and the go/no-go criteria of the screenin...
A new graphical method is described for analyzing the results of multiple inhibition experiments. It...
Left panel. Structure of the compounds. Right panel. Commercially available derivatives of FMP-40131...
A difficulty associated with high throughput screening for enzyme inhibitors is to establish reactio...
<p><b>A.</b> Scheme of the plate design in 96-well format for compounds screening. <b>B. Left, </b><...
<p>Enzyme activity in the presence of 100 μM compound (MMV# shown) was compared to activity of the e...
<p>Curves represent the sigmoidal fittings of the data, obtained in triplicates, on PmV inhibition b...
<p>(<b>A</b>) Inhibition potencies of the candidate compounds. The magnitudes of inhibition by compo...
<p>Scatter plot of primary screening data where the percentage of infected cells was normalized with...
<p>(A, B) Non-fluorescent inhibitors, compounds 3 and 14; the decrease in fluorescence is inhibited ...
<p>(A) Screening data of the 85 compounds investigated in the FluoPol assay. A 15% cut-off was set t...
Secreted active proteases, from families of enzymes such as matrix metalloproteinases (MMPs) and ADA...
(a-b) Preliminary screen outcome of 400 drug-like molecules in Pathogen Box as a measure of percenta...
<p>The plate format is shown. Column 1 contains maximum inhibition control (rifampicin) in Rows A–D ...
<div><p>A difficulty associated with high throughput screening for enzyme inhibitors is to establish...
<p>The different steps, the most relevant assay conditions and the go/no-go criteria of the screenin...
A new graphical method is described for analyzing the results of multiple inhibition experiments. It...
Left panel. Structure of the compounds. Right panel. Commercially available derivatives of FMP-40131...
A difficulty associated with high throughput screening for enzyme inhibitors is to establish reactio...
<p><b>A.</b> Scheme of the plate design in 96-well format for compounds screening. <b>B. Left, </b><...